HepaRegeniX develops a new and unique therapeutic concept to combat multiple liver diseases.
Find out more
Science
HepaRegeniX aims at curing liver diseases by reversing the disease path through liver regeneration. Along this path, the company is actively developing novel therapies for the treatment of both acute and chronic liver diseases.
Latest Press Releases
HepaRegeniX Scientific Founder Covers HRX-215 Development and Clincial Data in Plenary at the European Association for the Study of the Liver Congress 2025
Prof. Lars Zender’s featured talk described HepaRegeniX’s lead candidate and its potential in increasing liver regeneration, from initial target discovery and drug development towards Phase Ia clinical trial results Tuebingen, Germany, May 8, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, announced that the company’sContinue reading "HepaRegeniX Scientific Founder Covers HRX-215 Development and Clincial Data in Plenary at the European Association for the Study of the Liver Congress 2025"
HepaRegeniX completes €21.5 million financing to support clinical advancement of HRX-215 for liver regeneration
Tuebingen, Germany, April 15, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, today announced the second closing and completion of a €21.5 million financing round with the addition of Wellington Partners to its investor syndicate. HepaRegeniX plans to use the proceeds to complete its ongoingContinue reading "HepaRegeniX completes €21.5 million financing to support clinical advancement of HRX-215 for liver regeneration"